Profiling cancer testis antigens in non–small-cell lung cancer

• DOI: 10.1172/jci.insight.86837
• Publication Date: 2016-07-06T15:00:57Z
• Authors: Dijana Djureinovic; Björn M. Hallström; Masafumi Horie; Johanna Sofia Mar...; Linnea La Fleur; Linn Fagerberg; Hans Brunnström; Cecilia Lindskog; Katrin Madjar; Jörg Rahnenführer; Simon Ekman; Elisabeth Ståhle; Hirsh Koyi; Eva Brandén; Karolina Edlund; Jan G. Hengstler; Mats Lambe; Akira Saito; Johan Botling; Fredrik Pontén; Mathias Uhlén; Patrick Micke
• Keywords: Human Protein Atlas; Biomarker Discovery

Cancer testis antigens (CTAs) are of clinical interest as biomarkers and present valuable targets for immunotherapy. To comprehensively characterize the CTA landscape non-small-cell lung cancer (NSCLC), we compared RNAseq data from 199 NSCLC tissues to normal transcriptome 142 samples 32 different organs. Of 232 CTAs currently annotated in Caner Testis Database (CTdatabase), 96 were confirmed NSCLC. obtain an unbiased profile NSCLC, applied stringent criteria on our set defined 90 genes CTAs, which 55 not CTdatabase, thus representing potential new CTAs. Cluster analysis revealed that expression is histology dependent concurrent common. IHC tissue-specific protein selected (TKTL1, TGIF2LX, VCX, CXORF67). Furthermore, methylation was identified a regulatory mechanism based independent The Genome Atlas. proposed prognostic impact confirmed, neither cohort nor meta-analysis 1,117 cases. In summary, reliable including information expression, methylation, survival association. detailed catalog can guide biomarker studies efforts identify immunotherapeutic strategies.